Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Evotec Acquires Cell Culture Service GmbH

Published: Monday, January 07, 2013
Last Updated: Monday, January 07, 2013
Bookmark and Share
Acquisition strengthens cell-based screening and reagent platform at Evotec’s Hamburg site.

Evotec AG has announced the acquisition of all shares in Cell Culture Service GmbH (CCS). CCS is one of the leading suppliers of custom cells and cell-based reagents such as recombinant assay cell lines, assay-ready Frozen Instant Cells, qualified membranes, and proteins for high throughput screening with more than ten years experience in bulk cell production.

Strengthening Evotec’s position as quality leader in drug discovery solutions

The acquisition of CCS confirms Evotec’s leading position as a fully integrated drug discovery and early development partner for Pharma and biotechnology companies. Integration of CCS’ unique capabilities, such as frozen cell preparations and bulk cell transfection for cell-based screening will enable Evotec’s partners to access the latest science and the best-in-class technology infrastructure to increase efficiency in the drug discovery process.

CCS’ large scale processes for cell production, freezing and storage including the entire team of specialised cell culture scientists and technicians will be fully integrated into Evotec’s Hamburg operations to realise cost synergies and efficiency improvements.

“Through the acquisition of CCS, Evotec strengthens its cell culture capabilities and gains access to a growing base of customers using cell- based assays in their drug discovery processes. CCS’ experience and technologies for large scale cell production are a perfect fit with Evotec’s screening and in vitro pharmacology activities”, said Dr Mario Polywka, Chief Operating Officer of Evotec AG.

Dr Oliver Wehmeier, CEO of CCS, adds: “We are excited to join forces with Evotec. Our portfolio of custom products perfectly complements Evotec’s integrated service offering. In return, our customers, who have relied on CCS’ products and services for many years, will gain access to Evotec's broad range of screening technologies, which add a tremendous value to the assay-ready cells and cell-based reagents we provide.”

Transaction structure reflects value potential

The purchase price consists of a cash consideration of €1.15 m and an earn-out component targeting €1.05 m in cash. The earn-out component will become due following one year after the acquisition and depends upon the achievement of certain revenue targets.

Despite cash requirements for the transaction and integration of approximately €1.2 m in 2012, Evotec confirms its cash guidance for the full year of more than €60 m.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,400+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Evotec Achieves Clinical Development Milestone from Bayer
Company announces milestone achieved for the progression of a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec.
Thursday, August 04, 2016
Evotec Enters License Agreement with Broad Institute
Company has entered into a licence agreement with MIT for the use of CRISPR-Cas9 gene editing technology.
Thursday, July 07, 2016
Evotec Extends Integrated Drug Discovery Alliance With Genentech
Evotec and Genentech will continue their drug discovery alliance for a further three years.
Tuesday, May 24, 2016
Evotec, Ex Scientia Partner
Evotec and ex scientia announce partnership to discover bispecific small molecule immuno-oncology therapeutics.
Tuesday, April 26, 2016
Evotec Awarded Contract to Manage NCI CBC Screening Libraries Center
Company will provide compound management services for a period of five years.
Friday, October 09, 2015
Evotec AG Increases Its Revenue Guidance For 2015
All other elements of the Company’s financial guidance as of 12 May 2015 are confirmed.
Tuesday, September 15, 2015
Evotec Enters into Agreement with Pfizer
Licence and collaboration agreement in the field of tissue fibrosis.
Friday, September 11, 2015
Evotec, Apeiron Biologics and Sanofi Collaborate
Evotec AG and Apeiron Biologics AG, a biotech company with a focus on immunological approaches to treat cancer, have announced a strategic collaboration with Sanofi to develop novel small molecule-based cancer immunotherapies.
Monday, August 10, 2015
Evotec & Facio Partner
Facio partners with Evotec and initiates FSHD drug discovery programme.
Friday, May 08, 2015
Evotec and C4XD Enter Collaboration
Collaboration leverages the breadth & experience of Evotec's drug discovery infrastructure across chemistry & biology.
Tuesday, January 20, 2015
Evotec and Padlock Therapeutics Extend Collaboration
Evotec and Padlock Therapeutics announce initial success and extension of long-term collaboration.
Friday, January 09, 2015
Evotec and Sanofi Enter into Exclusive Negotiations
Goal to improve innovation effectiveness in drug discovery and pre-clinical development.
Thursday, December 04, 2014
Evotec And The Jain Foundation Expand Collaboration
The collaboration marks the start of multiple drug screening programmes.
Monday, September 15, 2014
Evotec, Medicines for Malaria Announce Compound Management Collaboration
The collaboration will support MMV’s Malaria and Pathogen Box initiatives.
Tuesday, August 19, 2014
Evotec, Fraunhofer in Drug Discovery Collaboration
The exclusive, strategic collaboration will combine the relevant platforms of both organisations, focusing on several disease areas.
Tuesday, July 08, 2014
Scientific News
Adoption of Three Dimensional Culture Models May Save Lives
Physiologically relevant cell models can detect chronic hepatotoxicity early in the drug discovery process.
Shedding Light on HIV Vaccine Design
Broadly speaking - Mathematical modelling of host-pathogen coevolution sheds light on HIV vaccine design.
AACC 2016 Sees Clinical Chemistry Labs Drive Precision Medicine Offerings
Biomarker assays to enable precision medicine and risk assessment, mass spec-based tests designed for use in clinical labs large and small, and liquid biopsy technology captured the spotlight at the AACC annual meeting.
Diverse Fungi Secrete Similar Suite of Decomposition Enzymes
A recent study reveals different fungal species secrete a rich set of enzymes that share similar functions, despite species-specific differences in the amino acid sequences of these enzymes.
Lower Mortality with Polyunsaturated Fat
In a study from Uppsala University the fatty acid linoleic acid (Omega 6) in subcutaneous adipose tissue was linked to lower mortality among older men followed over a 15-year period.
'Missing Evolutionary Link' of a Widely Used Natural Drug Source Found
A well-known family of natural compounds, called “terpenoids,” have a curious evolutionary origin. In particular, one question relevant to future drug discovery has puzzled scientists: exactly how does Nature make these molecules?
‘Lead Actors’ in Immune Cell Development
A new study, led by scientists at The Scripps Research Institute (TSRI), reveals a surprising twist in immune biology.
Probing How CRISPR-Cas9 Works
New study in Journal of Cell Biology examines DNA targeting dynamics in live cells.
Microbiome Impacts Tissue Repair, Regeneration
Researchers at the Stowers Institute have established a definitive link between the makeup of the microbiome, the host immune response, and an organism’s ability to heal itself.
Diagnosing Tumors of Unknown Origin
EPICUP® test is a tool that helps to identify up to 87% of cancers of unknown origin (COD).
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!